ATRX Adhera Therapeutics, Inc.
Stock Price & Overview

$0.030.008 (+36.36%)3:48 PM 09/29/23

OTCQB | $USD | Market Close

Quant Ranking

Analysis

News

Latest Headlines

Adhera Therapeutics files for Nasdaq uplisting, $35M offering

Adhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplist

Adhera Therapeutics signs letter of intent to acquire cancer therapy

Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq

Adhera Therapeutics provides update on mid-stage MLR-1019 Parkinson’s disease trial

Adhera gets European patent covering MLR-1019

Adhera inks exclusive license agreement with Melior Pharmaceuticals for MLR-1023

Adhera signs definitive license agreement with Melior for Parkinson’s disease drug candidate

Adhera Therapeutics inks LOI for potential Parkinson’s disease treatment

Adhera Therapeutics reports Q3 results

Company Profile

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Sector

Health Care

Industry

Biotechnology

Employees

Founded

Address